HF-REVERT (Follow-up)

Phase 2, Multicentre, Randomised, Double-blind, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial Infarction